Key Points
- Alpha Tau Medical CFO Raphi Levy sold 20,000 shares on June 25 at an average price of $11.00, totaling $220,000. The sale reduced his ownership by about 15.36%, and it was made under a pre-arranged Rule 10b5-1 plan.
- Levy has also sold shares earlier in the month, including 17,500 shares on June 23 and 32,500 shares on June 3, signaling a pattern of insider selling.
- The company recently missed quarterly earnings expectations, reporting EPS of -$0.26 versus the -$0.13 consensus. Despite mixed analyst views, the stock has risen near its 52-week high of $11.62.
Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 20,000 shares of Alpha Tau Medical stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00. Following the transaction, the chief financial officer directly owned 110,180 shares of the company's stock, valued at approximately $1,211,980. This trade represents a 15.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raphi Levy also recently made the following trade(s):
- On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
- On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.
Alpha Tau Medical Stock Performance
NASDAQ DRTS opened at $10.88 on Friday. The stock has a market cap of $982.79 million, a PE ratio of -16.24 and a beta of 1.19. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The firm has a 50-day moving average of $9.39 and a 200-day moving average of $7.61. Alpha Tau Medical Ltd. has a 52-week low of $2.87 and a 52-week high of $11.62.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). On average, sell-side analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on DRTS. Piper Sandler increased their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a "neutral" rating in a research note on Tuesday, May 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, May 12th. Citigroup lifted their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, March 11th. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alpha Tau Medical presently has an average rating of "Hold" and an average target price of $12.60.
Read Our Latest Analysis on Alpha Tau Medical
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in DRTS. Apella Capital LLC bought a new stake in shares of Alpha Tau Medical during the 4th quarter valued at about $1,892,000. Daytona Street Capital LLC acquired a new position in Alpha Tau Medical in the fourth quarter valued at approximately $749,000. Mariner LLC lifted its stake in Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company's stock valued at $620,000 after buying an additional 1,915 shares during the period. Millennium Management LLC boosted its holdings in shares of Alpha Tau Medical by 185.7% during the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company's stock worth $534,000 after buying an additional 70,081 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical during the 1st quarter worth approximately $286,000. 2.65% of the stock is owned by institutional investors and hedge funds.
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
